This randomized controlled trial compared haloperidol along with conventional therapy to placebo along with conventional therapy for gastroparesis in the emergency department. The primary outcomes of pain and nausea scores at 1 hour were significantly improved in the haloperidol group, but not in the placebo group. In this summary, we discuss a quality assessment of the article and summarized the social media commentary from the blog post/podcast.
G
astroparesis is a common complaint in the emergency department (ED), with the most common causes being diabetes, surgery, and idiopathic. 1 Metoclopramide is currently the only drug approved by the FDA for treatment. 2 Various alternative therapies are used, with haloperidol showing promise due to its effects on dopamine receptors and utility in the postoperative setting. [3] [4] [5] [6] This study aimed to compare haloperidol in addition to conventional therapy versus conventional therapy alone for the management of acute gastroparesis in an ED setting.
ARTICLE SUMMARY
This is a randomized, double-blind, placebo-controlled trial comparing haloperidol 5 mg IV to placebo. Patients in both groups were treated with conventional therapy as deemed appropriate by the treating physician. Patients were eligible for the study if they had a prior diagnosis of gastroparesis and presented with symptoms of nausea, vomiting, and abdominal pain. Patients younger than 18, with prolonged QT, systolic pressure < 90 mm Hg, other causes of abdominal pathology, allergy to haloperidol, pregnancy, or incarceration or those with an inability to give consent were excluded. Thirty-three patients were included in the analysis. Significant reductions in both pain and nausea scores were seen in the haloperidol group but not in the control group.
QUALITY ASSESSMENT
This was a well-done randomized, controlled trial of ED patients. The most important weakness of this trial is the very small sample size, resulting in wide confidence intervals. Furthermore, they were unable to recruit the full sample indicated by their power calculation. Although the authors report no significant demographic differences, some large and potentially clinically important differences were noted between the groups. For example, 40% of the haloperidol group received morphine compared to 28% of the placebo group. Similarly, 53% of the haloperidol group received ondansetron compared to only 28% of the placebo group. These baseline imbalances could have affected the results in such a small trial. There were two primary outcomes (when there really should only be one) that examined pain and nausea at 1 hour. A longer follow-up period may be a more patient important outcome. Finally, although the results are very promising in terms of efficacy, the study was too small to make any conclusions about the safety of this therapeutic strategy.
KEY RESULTS
Fifteen patients were randomized to the haloperidol group and 18 to the control group. For the outcome of pain, scores decreased from a mean of 8.5 to 3.1 with haloperidol (p < 0.001) and 8.3 to 7.2 in the control group (p = 0.11) on a 10-point visual analog scale (VAS). Using a 5-point VAS, nausea decreased from a mean of 4.5 to 1.8 with haloperidol (p < 0.001) and a mean of 4.1 to 3.4 with placebo (p = 0.05). Fewer patients were admitted to the hospital from the haloperidol group (27% vs 72%, p = 0.009), and length of stay was shorter but statistically unchanged (5 hours vs. 9 hours, p = 0.77).
AUTHORS' COMMENTS
While the sample size was small and there were some baseline imbalances between the groups, the data in this study suggest that haloperidol, when used in conjunction with standard therapies for gastroparesis, leads to improved pain and nausea scores, as well as possibly fewer admissions and a shorter length of stay.
TOP SOCIAL MEDIA COMMENTARY
Comments from theSGEM.com Megan Groth, PharmD: I really appreciate the discussion surrounding the concern with QTc prolongation with haloperidol. This is one of those warnings that comes up with a number of drugs, but my level of concern (as a pharmacist) isn't always the same. For example, the QTc prolongation risk with 4 mg of IV ondansetron isn't the same as 32 mg of ondansetron. And that risk isn't necessarily equivalent to the risk with other medications like methadone, ziprasidone, levofloxacin, or azithromycin. The problem is, there isn't a lot of literature out there detailing the magnitude of risk for each of these medications (or at different doses), but the drug interaction/warning software may make it appear as though the level of concern should be similar.
The other point I would bring up that was briefly mentioned is the feasibility of ECG monitoring in a patient who is nauseous versus the "typical" patient who is receiving haloperidol in the ED (e.g., the acutely agitated, potentially violent patient). As the author mentioned, we may not be used to getting ECGs for a patient who needs emergency administration of an antipsychotic, but perhaps it's more "doable" for the patient with gastroparesis or nausea/vomiting. As a pharmacist, if I were asked about the QTc prolongation in a patient where the provider wanted to use haloperidol, I'd probably look to see if we had any ECG data on file for the patient to evaluate whether or not they had a prolonged QTc at baseline, then check to see if there were any other drugs in their medication regimen which could prolong the QTc, and then come to a determination about whether or not I felt strongly that they should get another ECG before giving the haloperidol.
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Comments From Twitter Anton Helman @EMCases: After examining the evidence . . . Recently treated a bounce-back cyclical vomit pt who had 3 antiemetics previous visit. 1 dose of Haldol 5mg and pt went home smiling. Wonder about long term outcomes though?
Ryan Radecki @EMLitofNote: Unfortunately, a very small, difficult to generalize trial. That said, butyrophenones have been used for nausea and vomiting for decades, and this is essentially just an alternative to our steadily disappearing droperidol.
Twitter Poll
Take-to-work Points In a small but well-performed randomized clinical trial, haloperidol in addition to standard therapies improved pain and nausea scores for patients with acute gastroparesis presenting to the ED.
